The dynamics of the acne vulgaris market are anticipated
to change in the coming years owing to the increase in the
prevalent cases of acne vulgaris, along with the expected launch of
emerging therapies.
LAS VEGAS, May 27, 2024 /PRNewswire/ -- DelveInsight's
Acne Vulgaris Market Insights report includes a
comprehensive understanding of current treatment practices, acne
vulgaris emerging drugs, market share of individual therapies, and
current and forecasted market size from 2020 to 2034, segmented
into 7MM [the United States, the
EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Acne Vulgaris Market Report
- According to DelveInsight's analysis, the market size for acne
vulgaris is expected to grow significantly by 2034.
- As per DelveInsight's estimates, acne vulgaris affects
80% of Americans at some time during their lives. This rate
is expected to increase in the forecasted period.
- About 9.4% of people worldwide have acne vulgaris, with
teens having the highest prevalence of the condition. In all ethnic
groupings, it affects more than 90% of men and 80% of
women.
- Leading acne vulgaris companies such as Dermata
Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma,
Incyte Corporation, and others are developing novel acne
vulgaris drugs that can be available in the acne vulgaris market in
the coming years.
- The promising acne vulgaris therapies in the pipeline
include DMT310, Anifrolumab, CFZ533, Bimekizumab,
Povorcitinib, among others.
Discover which therapies are expected to grab the major acne
vulgaris market share @ Acne Vulgaris Market Report
Acne Vulgaris Overview
Acne vulgaris, commonly known as acne, is a prevalent skin
condition that affects millions of people worldwide, typically
during adolescence but can persist into adulthood. It occurs when
hair follicles become clogged with oil and dead skin cells, leading
to the formation of pimples, blackheads, whiteheads, and in more
severe cases, nodules and cysts.
The causes of acne vulgaris are multifactorial and include
hormonal changes, genetics, excess oil production, bacteria
(Propionibacterium acnes), inflammation, and certain medications.
Hormonal fluctuations, such as those during puberty, menstruation,
pregnancy, or hormonal disorders, can trigger or exacerbate acne by
increasing oil production and causing skin cells to become sticky
and clog pores.
Symptoms of acne vulgaris vary from person to person and can
range from mild to severe. Common symptoms include the presence of
blackheads (open comedones), whiteheads (closed comedones), papules
(small, red bumps), pustules (pimples containing pus), nodules
(large, painful lumps beneath the surface of the skin), and cysts
(deep, pus-filled lesions). These lesions primarily appear on the
face, neck, chest, back, and shoulders.
Diagnosing acne vulgaris typically involves a physical
examination of the skin by a healthcare professional, who assesses
the type and severity of lesions present. Medical history,
including family history of acne, hormonal fluctuations, and
medication use, may also be considered. In some cases, additional
tests, such as hormone level measurements or skin cultures, may be
performed to rule out underlying conditions or infections
contributing to acne.
Acne Vulgaris Epidemiology Segmentation
The acne vulgaris epidemiology section provides insights into
the historical and current acne vulgaris patient pool and
forecasted trends for the 7MM. It helps recognize the causes of
current and forecasted patient trends by exploring numerous studies
and views of key opinion leaders.
The acne vulgaris market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Prevalent Cases of Acne Vulgaris
- Gender-specific Prevalent Cases of Acne Vulgaris
- Severity-specific Prevalent Cases of Acne Vulgaris
- Diagnosed and Treatable Cases of Acne Vulgaris
Acne Vulgaris Treatment Market
The treatment of acne is tailored to factors such as age,
gender, the severity of the condition, its duration, and how well
previous treatments have worked. Retinoids and similar medications
containing retinoic acids or tretinoin are commonly prescribed for
moderate acne. These medications are available in various forms
like creams, gels, and lotions, including examples such as
tretinoin (sold as Avita, Retin-A, among others), adapalene
(marketed as Differin), and tazarotene (sold under the brand names
Tazorac, Avage, among others). However, it's important to note
that using topical retinoids can heighten the skin's sensitivity to
sunlight and may lead to dryness and redness, particularly in
individuals with darker skin tones.
Antibiotics function by eliminating excessive bacteria on the
skin and diminishing redness and swelling. They're often paired
with benzoyl peroxide to decrease the risk of bacteria becoming
resistant. Examples of these combinations include clindamycin with
benzoyl peroxide (sold as Benzaclin, Duac, among others) and
erythromycin with benzoyl peroxide (sold as Benzamycin). Using
only topical antibiotics is not advisable. Sarecycline, a new type
of oral antibiotic derived from tetracycline, was approved by the
FDA in the US in 2018 for treating moderate-to-severe acne vulgaris
in individuals aged 9 and older. It can be ingested with or without
food and has a narrow spectrum of activity.
Due to the multifactorial etiology of acne vulgaris, most drugs
cannot meet the treatment requirements. Therefore, the screening
and development of excellent drugs are one of the key targets for
treating acne in the future.
To know more about acne vulgaris treatment guidelines, visit @
Acne Vulgaris Management
Acne Vulgaris Pipeline Therapies and Key Companies
- DMT310: Dermata Therapeutics
- Anifrolumab: AstraZeneca
- CFZ533: Novartis Pharmaceuticals
- Bimekizumab: UCB Pharma
- Povorcitinib: Incyte Corporation
Learn more about the FDA-approved drugs for acne vulgaris @
Drugs for Acne Vulgaris Treatment
Acne Vulgaris Market Dynamics
The dynamics of the acne vulgaris market are expected to change
in the coming years. Acne vulgaris market growth is primarily
driven by the increasing prevalence of acne cases worldwide,
particularly among adolescents and young adults. Factors such as
hormonal changes, lifestyle habits, and genetic
predispositions contribute to the persistent demand for
effective acne treatments. Moreover, the growing awareness about
skincare and beauty standards fuels the demand for advanced
therapeutic solutions, creating opportunities for market
expansion.
Furthermore, many potential therapies are being investigated for
the treatment of acne vulgaris, and it is safe to predict that the
treatment space will significantly impact the acne
vulgaris market during the forecast period. Moreover, the
anticipated introduction of emerging therapies with improved
efficacy and a further improvement in the diagnosis rate are
expected to drive the growth of the acne vulgaris market in
the 7MM.
However several factors may impede the growth of the acne
vulgaris market. One primary challenge is the complex nature of
acne, which varies widely in severity and underlying causes
among individuals. This variability complicates the development
of universally effective treatments, leading to a fragmented
market with diverse products of varying efficacy. Additionally,
regulatory hurdles, such as stringent approval processes for
new medications and treatments, pose challenges for companies
seeking to bring innovative solutions to the acne vulgaris
market. Furthermore, the social stigma surrounding acne
often leads to underreporting and undertreatment, impacting both
patient outcomes and market demand.
Moreover, acne vulgaris treatment poses a significant
economic burden and disrupts patients' overall well-being and
QOL. Furthermore, the acne vulgaris market growth may be offset by
failures and discontinuation of emerging therapies,
unaffordable pricing, market access and reimbursement
issues, and a shortage of healthcare specialists. In
addition, the undiagnosed, unreported cases and the
unawareness about the disease may also impact the acne vulgaris
market growth.
Acne Vulgaris Market
Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Acne Vulgaris
Companies
|
Dermata Therapeutics,
AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte
Corporation, and others
|
Key Pipeline Acne Vulgaris Therapies
|
DMT310, Anifrolumab,
CFZ533, Bimekizumab, Povorcitinib,
and others
|
Scope of the Acne Vulgaris Market
Report
- Therapeutic Assessment: Acne Vulgaris current
marketed and emerging therapies
- Acne Vulgaris Market Dynamics: Key
Market Forecast Assumptions of Emerging Acne Vulgaris Drugs and
Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Acne Vulgaris
Market Access and Reimbursement
Discover more about acne vulgaris drugs in development @
Acne Vulgaris Clinical Trials
Table of Contents
1.
|
Acne Vulgaris
Key Insights
|
2.
|
Acne Vulgaris
Report Introduction
|
3.
|
Acne Vulgaris Overview
at a Glance
|
4.
|
Acne Vulgaris
Executive Summary
|
5
|
Acne Vulgaris
Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Acne Vulgaris
Treatment and Management
|
8.
|
Acne Vulgaris
Guidelines
|
9.
|
Acne Vulgaris
Epidemiology and Patient
Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in Acne
Vulgaris
|
12.
|
Acne Vulgaris Marketed
Drugs
|
13.
|
Acne Vulgaris
Emerging Drugs
|
14.
|
7MM Acne Vulgaris Market
Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Acne Vulgaris Pipeline
Acne Vulgaris Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key acne vulgaris companies, including
Novan Inc., Bausch Health Americas Inc., AOBiome LLC, Ascletis
Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals, Shanghai
Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc.,
Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma,
Dermavant Sciences, Eligo Bioscience, Cassiopea, Inc., BioPharmX,
Madam Therapeutics, SiSaf, among others.
Acne Vulgaris Epidemiology Forecast
Acne Vulgaris Epidemiology Forecast – 2032 report
delivers an in-depth understanding of the disease, historical and
forecasted acne vulgaris epidemiology in the 7MM, i.e.,
the United States, EU5
(Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Severe Acne Vulgaris Market
Severe Acne Vulgaris Market Insights, Epidemiology, and
Market Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key severe acne vulgaris companies, including
Ascletis Pharmaceuticals, BioPharmX Corporation, Biofrontera,
Boston Pharmaceuticals, Botanix Pharmaceuticals, Shanghai
Fudan-Zhangjiang Bio-Pharmaceutical, Vyne Therapeutics Inc.,
DERMATA THERAPEUTICS, Novan, among others.
Severe Acne Vulgaris Pipeline
Severe Acne Vulgaris Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key severe acne vulgaris companies,
including Ascletis Pharmaceuticals, BioPharmX Corporation,
Biofrontera, Boston Pharmaceuticals, Botanix Pharmaceuticals,
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Vyne Therapeutics
Inc., DERMATA THERAPEUTICS, Novan, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/acne-vulgaris-market-to-register-sustainable-growth-by-2034-examines-delveinsight--key-companies---dermata-therapeutics-astrazeneca-novartis-pharmaceuticals-ucb-pharma-incyte-corporation-302155865.html